BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32800727)

  • 1. Two-stage Study of Familial Prostate Cancer by Whole-exome Sequencing and Custom Capture Identifies 10 Novel Genes Associated with the Risk of Prostate Cancer.
    Schaid DJ; McDonnell SK; FitzGerald LM; DeRycke L; Fogarty Z; Giles GG; MacInnis RJ; Southey MC; Nguyen-Dumont T; Cancel-Tassin G; Cussenot O; Whittemore AS; Sieh W; Ioannidis NM; Hsieh CL; Stanford JL; Schleutker J; Cropp CD; Carpten J; Hoegel J; Eeles R; Kote-Jarai Z; Ackerman MJ; Klein CJ; Mandal D; Cooney KA; Bailey-Wilson JE; Helfand B; Catalona WJ; Wiklund F; Riska S; Bahetti S; Larson MC; Cannon Albright L; Teerlink C; Xu J; Isaacs W; Ostrander EA; Thibodeau SN
    Eur Urol; 2021 Mar; 79(3):353-361. PubMed ID: 32800727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations in ATM, NBN and BRCA2 predispose to aggressive prostate cancer in Poland.
    Wokołorczyk D; Kluźniak W; Huzarski T; Gronwald J; Szymiczek A; Rusak B; Stempa K; Gliniewicz K; Kashyap A; Morawska S; Dębniak T; Jakubowska A; Szwiec M; Domagała P; Lubiński J; Narod SA; Akbari MR; Cybulski C;
    Int J Cancer; 2020 Nov; 147(10):2793-2800. PubMed ID: 32875559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germline Sequencing Analysis to Inform Clinical Gene Panel Testing for Aggressive Prostate Cancer.
    Darst BF; Saunders E; Dadaev T; Sheng X; Wan P; Pooler L; Xia LY; Chanock S; Berndt SI; Wang Y; Patel AV; Albanes D; Weinstein SJ; Gnanapragasam V; Huff C; Couch FJ; Wolk A; Giles GG; Nguyen-Dumont T; Milne RL; Pomerantz MM; Schmidt JA; Travis RC; Key TJ; Stopsack KH; Mucci LA; Catalona WJ; Marosy B; Hetrick KN; Doheny KF; MacInnis RJ; Southey MC; Eeles RA; Wiklund F; Conti DV; Kote-Jarai Z; Haiman CA
    JAMA Oncol; 2023 Nov; 9(11):1514-1524. PubMed ID: 37733366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.
    Klein EA; Cooperberg MR; Magi-Galluzzi C; Simko JP; Falzarano SM; Maddala T; Chan JM; Li J; Cowan JE; Tsiatis AC; Cherbavaz DB; Pelham RJ; Tenggara-Hunter I; Baehner FL; Knezevic D; Febbo PG; Shak S; Kattan MW; Lee M; Carroll PR
    Eur Urol; 2014 Sep; 66(3):550-60. PubMed ID: 24836057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel.
    Leongamornlert DA; Saunders EJ; Wakerell S; Whitmore I; Dadaev T; Cieza-Borrella C; Benafif S; Brook MN; Donovan JL; Hamdy FC; Neal DE; Muir K; Govindasami K; Conti DV; Kote-Jarai Z; Eeles RA
    Eur Urol; 2019 Sep; 76(3):329-337. PubMed ID: 30777372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole exome sequencing in 75 high-risk families with validation and replication in independent case-control studies identifies TANGO2, OR5H14, and CHAD as new prostate cancer susceptibility genes.
    Karyadi DM; Geybels MS; Karlins E; Decker B; McIntosh L; Hutchinson A; Kolb S; McDonnell SK; Hicks B; Middha S; FitzGerald LM; DeRycke MS; Yeager M; Schaid DJ; Chanock SJ; Thibodeau SN; Berndt SI; Stanford JL; Ostrander EA
    Oncotarget; 2017 Jan; 8(1):1495-1507. PubMed ID: 27902461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.
    Risbridger GP; Taylor RA; Clouston D; Sliwinski A; Thorne H; Hunter S; Li J; Mitchell G; Murphy D; Frydenberg M; Pook D; Pedersen J; Toivanen R; Wang H; Papargiris M; Lawrence MG; Bolton DM
    Eur Urol; 2015 Mar; 67(3):496-503. PubMed ID: 25154392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutational landscape of candidate genes in familial prostate cancer.
    Johnson AM; Zuhlke KA; Plotts C; McDonnell SK; Middha S; Riska SM; Schaid DJ; Thibodeau SN; Douglas JA; Cooney KA
    Prostate; 2014 Oct; 74(14):1371-8. PubMed ID: 25111073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients.
    Kader AK; Sun J; Isaacs SD; Wiley KE; Yan G; Kim ST; Fedor H; DeMarzo AM; Epstein JI; Walsh PC; Partin AW; Trock B; Zheng SL; Xu J; Isaacs W
    Prostate; 2009 Aug; 69(11):1195-205. PubMed ID: 19434657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exome-based genome-wide association study and risk assessment using genetic risk score to prostate cancer in the Korean population.
    Oh JJ; Lee SJ; Hwang JY; Kim D; Lee SE; Hong SK; Ho JN; Yoon S; Sung J; Kim WJ; Byun SS
    Oncotarget; 2017 Jul; 8(27):43934-43943. PubMed ID: 28380453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The HOXB13 variant X285K is associated with clinical significance and early age at diagnosis in African American prostate cancer patients.
    Na R; Wei J; Sample CJ; Gielzak M; Choi S; Cooney KA; Rabizadeh D; Walsh PC; Zheng LS; Xu J; Isaacs WB
    Br J Cancer; 2022 Mar; 126(5):791-796. PubMed ID: 34799695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry Polygenic Risk Score Associated with Aggressive Disease in Men of African Ancestry.
    Chen F; Madduri RK; Rodriguez AA; Darst BF; Chou A; Sheng X; Wang A; Shen J; Saunders EJ; Rhie SK; Bensen JT; Ingles SA; Kittles RA; Strom SS; Rybicki BA; Nemesure B; Isaacs WB; Stanford JL; Zheng W; Sanderson M; John EM; Park JY; Xu J; Wang Y; Berndt SI; Huff CD; Yeboah ED; Tettey Y; Lachance J; Tang W; Rentsch CT; Cho K; Mcmahon BH; Biritwum RB; Adjei AA; Tay E; Truelove A; Niwa S; Sellers TA; Yamoah K; Murphy AB; Crawford DC; Patel AV; Bush WS; Aldrich MC; Cussenot O; Petrovics G; Cullen J; Neslund-Dudas CM; Stern MC; Kote-Jarai Z; Govindasami K; Cook MB; Chokkalingam AP; Hsing AW; Goodman PJ; Hoffmann TJ; Drake BF; Hu JJ; Keaton JM; Hellwege JN; Clark PE; Jalloh M; Gueye SM; Niang L; Ogunbiyi O; Idowu MO; Popoola O; Adebiyi AO; Aisuodionoe-Shadrach OI; Ajibola HO; Jamda MA; Oluwole OP; Nwegbu M; Adusei B; Mante S; Darkwa-Abrahams A; Mensah JE; Diop H; Van Den Eeden SK; Blanchet P; Fowke JH; Casey G; Hennis AJ; Lubwama A; Thompson IM; Leach R; Easton DF; Preuss MH; Loos RJ; Gundell SM; Wan P; Mohler JL; Fontham ET; Smith GJ; Taylor JA; Srivastava S; Eeles RA; Carpten JD; Kibel AS; Multigner L; Parent MÉ; Menegaux F; Cancel-Tassin G; Klein EA; Andrews C; Rebbeck TR; Brureau L; Ambs S; Edwards TL; Watya S; Chanock SJ; Witte JS; Blot WJ; Michael Gaziano J; Justice AC; Conti DV; Haiman CA
    Eur Urol; 2023 Jul; 84(1):13-21. PubMed ID: 36872133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased Prostate Cancer Glucose Metabolism Detected by
    Lavallée E; Bergeron M; Buteau FA; Blouin AC; Duchesnay N; Dujardin T; Tiguert R; Lacombe L; Fradet V; Makao-Nguile M; Fradet Y; Beauregard JM; Pouliot F
    Eur Urol Focus; 2019 Nov; 5(6):998-1006. PubMed ID: 29609897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic variants in cell cycle control pathway confer susceptibility to aggressive prostate carcinoma.
    Kibel AS; Ahn J; Isikbay M; Klim A; Wu WS; Hayes RB; Isaacs WB; Daw EW
    Prostate; 2016 Apr; 76(5):479-90. PubMed ID: 26708993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men.
    Preston MA; Gerke T; Carlsson SV; Signorello L; Sjoberg DD; Markt SC; Kibel AS; Trinh QD; Steinwandel M; Blot W; Vickers AJ; Lilja H; Mucci LA; Wilson KM
    Eur Urol; 2019 Mar; 75(3):399-407. PubMed ID: 30237027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring targets of TET2-mediated methylation reprogramming as potential discriminators of prostate cancer progression.
    Kamdar S; Isserlin R; Van der Kwast T; Zlotta AR; Bader GD; Fleshner NE; Bapat B
    Clin Epigenetics; 2019 Mar; 11(1):54. PubMed ID: 30917865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline Sequencing DNA Repair Genes in 5545 Men With Aggressive and Nonaggressive Prostate Cancer.
    Darst BF; Dadaev T; Saunders E; Sheng X; Wan P; Pooler L; Xia LY; Chanock S; Berndt SI; Gapstur SM; Stevens V; Albanes D; Weinstein SJ; Gnanapragasam V; Giles GG; Nguyen-Dumont T; Milne RL; Pomerantz M; Schmidt JA; Mucci L; Catalona WJ; Hetrick KN; Doheny KF; MacInnis RJ; Southey MC; Eeles RA; Wiklund F; Kote-Jarai Z; Conti DV; Haiman CA
    J Natl Cancer Inst; 2021 May; 113(5):616-625. PubMed ID: 32853339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Genes with Rare Loss of Function Variants Associated with Aggressive Prostate Cancer and Survival.
    Saunders EJ; Dadaev T; Brook MN; Wakerell S; Govindasami K; Rageevakumar R; Hussain N; Osborne A; Keating D; Lophatananon A; Muir KR; ; Darst BF; Conti DV; Haiman CA; Antoniou AC; Eeles RA; Kote-Jarai Z
    Eur Urol Oncol; 2024 Apr; 7(2):248-257. PubMed ID: 38458890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Searching for candidate genes in familial BRCAX mutation carriers with prostate cancer.
    Hunter SM; Rowley SM; Clouston D; ; Li J; Lupat R; Krishnananthan N; Risbridger G; Taylor R; Bolton D; Campbell IG; Thorne H
    Urol Oncol; 2016 Mar; 34(3):120.e9-16. PubMed ID: 26585945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.